首页 > 最新文献

Journal of Nuclear Medicine最新文献

英文 中文
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer. [225Ac]Ac-PSMA治疗[177Lu]Lu-PSMA炎症转移性Castion-Ristant前列腺癌症的临床经验。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-24 DOI: 10.2967/jnumed.123.265546
Nalan Alan-Selcuk, Gamze Beydagi, Emre Demirci, Meltem Ocak, Serkan Celik, Bala B Oven, Turkay Toklu, Ipek Karaaslan, Kaan Akcay, Omer Sonmez, Levent Kabasakal

For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [225Ac]Ac-PSMA are promising. We retrospectively analyzed the outcomes of patients treated with [225Ac]Ac-PSMA between December 2018 and October 2022. Methods: We evaluated the treatment results of 23 patients (mean age, 70.3 ± 8.8 y) with mCRPC who were refractory to treatment with [177Lu]Lu-PSMA (2-9 cycles). The safety profile was assessed according to Common Technology Criteria for Adverse Events version 5.0. Treatment efficacy was assessed using prostate-specific membrane antigen PET progression criteria and prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 2 criteria after the first cycle of [225Ac]Ac-PSMA treatment. Results: All patients received androgen-deprivation therapy, whereas 22 (96%) and 19 (83%) patients received chemotherapy and second-generation antiandrogen therapy, respectively. One patient received 4 cycles, 2 received 3 cycles, 8 received 2 cycles, and 12 received 1 cycle of [225Ac]Ac-PSMA. The median interval between cycles was 13 wk (range, 8-28 wk). [225Ac]Ac-PSMA was administered with a mean activity of 7.6 MBq (range, 6.2-10.0 MBq) in each cycle. Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patients (26%) after [225Ac]Ac-PSMA treatment, there was at least some level of decline in PSA observed in 11 patients (58%; n = 19). Treatment response was assessed in patients who underwent [68Ga]Ga-PSMA PET/CT imaging. After the first cycle of treatment (n = 18), 50% of patients (n = 9) showed disease progression according to prostate-specific membrane antigen PET progression criteria, and the disease control rate was calculated to be 50%. Median progression-free survival was 3.1 mo, and median overall survival was 7.7 mo. Grade 3 hematologic toxicity occurred in 1 patient, and grade 3 nephrotoxicity was observed in another patient. Parotid SUVmax decreased by 33%, although all patients complained of dry mouth before treatment. Conclusion: We observed that [225Ac]Ac-PSMA therapy was safe and showed potential even in cases with advanced-stage mCRPC in which all other treatment options were completed.

对于对[177Lu]Lu-PSMA治疗无反应的晚期转移性去势耐受性癌症(mCRPC)患者,治疗选择有限。[225Ac]Ac-PSMA获得的临床结果是有希望的。我们回顾性分析了2018年12月至2022年10月期间接受[225Ac]Ac-PSMA治疗的患者的结果。方法:我们对23例患者(平均年龄70.3岁)的治疗结果进行了评估 ± 8.8 y) mCRPC对[177Lu]Lu-PSMA治疗无效(2-9个周期)。根据5.0版不良事件通用技术标准对安全性进行评估。在[225Ac]Ac-PSMA治疗的第一个周期后,根据前列腺癌症工作组2标准,使用前列腺特异性膜抗原PET进展标准和前列腺特异性抗原(PSA)反应评估治疗效果。结果:所有患者都接受了雄激素剥夺治疗,而22名(96%)和19名(83%)患者分别接受了化疗和第二代抗雄激素治疗。1名患者接受4个周期,2名患者接受3个周期,8名患者接受2个周期,12名患者接受1个周期 [225Ac]Ac-PSMA的周期。中位周期间隔为13周(范围为8-28周)。[225Ac]Ac-PSMA在每个周期中的平均活性为7.6MBq(范围6.2-10.0MBq)。患者处于疾病的晚期,肿瘤负担非常高。尽管在[225Ac]Ac-PSMA治疗后,5名患者(26%)的PSA反应最好,但在11名患者(58%;n=19)中观察到PSA至少有一定程度的下降。在接受[68Ga]Ga-PSMA PET/CT成像的患者中评估治疗反应。在第一个治疗周期(n=18)后,根据前列腺特异性膜抗原PET进展标准,50%的患者(n=9)显示出疾病进展,疾病控制率计算为50%。中位无进展生存期为3.1 mo,中位总生存率为7.7 mo.1例患者出现3级血液学毒性,另1例患者观察到3级肾毒性。Parotid SUVmax下降了33%,尽管所有患者在治疗前都抱怨口干。结论:我们观察到[225Ac]Ac-PSMA治疗是安全的,即使在所有其他治疗方案都已完成的晚期mCRPC病例中也显示出潜力。
{"title":"Clinical Experience with [<sup>225</sup>Ac]Ac-PSMA Treatment in Patients with [<sup>177</sup>Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.","authors":"Nalan Alan-Selcuk,&nbsp;Gamze Beydagi,&nbsp;Emre Demirci,&nbsp;Meltem Ocak,&nbsp;Serkan Celik,&nbsp;Bala B Oven,&nbsp;Turkay Toklu,&nbsp;Ipek Karaaslan,&nbsp;Kaan Akcay,&nbsp;Omer Sonmez,&nbsp;Levent Kabasakal","doi":"10.2967/jnumed.123.265546","DOIUrl":"10.2967/jnumed.123.265546","url":null,"abstract":"<p><p>For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [<sup>177</sup>Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [<sup>225</sup>Ac]Ac-PSMA are promising. We retrospectively analyzed the outcomes of patients treated with [<sup>225</sup>Ac]Ac-PSMA between December 2018 and October 2022. <b>Methods:</b> We evaluated the treatment results of 23 patients (mean age, 70.3 ± 8.8 y) with mCRPC who were refractory to treatment with [<sup>177</sup>Lu]Lu-PSMA (2-9 cycles). The safety profile was assessed according to Common Technology Criteria for Adverse Events version 5.0. Treatment efficacy was assessed using prostate-specific membrane antigen PET progression criteria and prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 2 criteria after the first cycle of [<sup>225</sup>Ac]Ac-PSMA treatment. <b>Results:</b> All patients received androgen-deprivation therapy, whereas 22 (96%) and 19 (83%) patients received chemotherapy and second-generation antiandrogen therapy, respectively. One patient received 4 cycles, 2 received 3 cycles, 8 received 2 cycles, and 12 received 1 cycle of [<sup>225</sup>Ac]Ac-PSMA. The median interval between cycles was 13 wk (range, 8-28 wk). [<sup>225</sup>Ac]Ac-PSMA was administered with a mean activity of 7.6 MBq (range, 6.2-10.0 MBq) in each cycle. Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patients (26%) after [<sup>225</sup>Ac]Ac-PSMA treatment, there was at least some level of decline in PSA observed in 11 patients (58%; <i>n</i> = 19). Treatment response was assessed in patients who underwent [<sup>68</sup>Ga]Ga-PSMA PET/CT imaging. After the first cycle of treatment (<i>n</i> = 18), 50% of patients (<i>n</i> = 9) showed disease progression according to prostate-specific membrane antigen PET progression criteria, and the disease control rate was calculated to be 50%. Median progression-free survival was 3.1 mo, and median overall survival was 7.7 mo. Grade 3 hematologic toxicity occurred in 1 patient, and grade 3 nephrotoxicity was observed in another patient. Parotid SUV<sub>max</sub> decreased by 33%, although all patients complained of dry mouth before treatment. <b>Conclusion:</b> We observed that [<sup>225</sup>Ac]Ac-PSMA therapy was safe and showed potential even in cases with advanced-stage mCRPC in which all other treatment options were completed.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10068799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment and Governance. 医学成像中人工智能的伦理考量:部署和治理。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-24 DOI: 10.2967/jnumed.123.266110
Jonathan Herington, Melissa D McCradden, Kathleen Creel, Ronald Boellaard, Elizabeth C Jones, Abhinav K Jha, Arman Rahmim, Peter J H Scott, John J Sunderland, Richard L Wahl, Sven Zuehlsdorff, Babak Saboury

The deployment of artificial intelligence (AI) has the potential to make nuclear medicine and medical imaging faster, cheaper, and both more effective and more accessible. This is possible, however, only if clinicians and patients feel that these AI medical devices (AIMDs) are trustworthy. Highlighting the need to ensure health justice by fairly distributing benefits and burdens while respecting individual patients' rights, the AI Task Force of the Society of Nuclear Medicine and Molecular Imaging has identified 4 major ethical risks that arise during the deployment of AIMD: autonomy of patients and clinicians, transparency of clinical performance and limitations, fairness toward marginalized populations, and accountability of physicians and developers. We provide preliminary recommendations for governing these ethical risks to realize the promise of AIMD for patients and populations.

人工智能的部署有可能使核医学和医学成像更快、更便宜、更有效、更容易获得。然而,只有临床医生和患者认为这些人工智能医疗设备(AIMD)是值得信赖的,这才有可能实现。核医学和分子成像学会人工智能工作组强调,需要通过公平分配利益和负担,同时尊重个体患者的权利,确保健康正义,并确定了AIMD部署过程中出现的4个主要道德风险:患者和临床医生的自主权、临床表现的透明度和局限性,对边缘化人群的公平,以及医生和开发人员的问责制。我们为管理这些道德风险提供了初步建议,以实现AIMD对患者和人群的承诺。
{"title":"Ethical Considerations for Artificial Intelligence in Medical Imaging: Deployment and Governance.","authors":"Jonathan Herington, Melissa D McCradden, Kathleen Creel, Ronald Boellaard, Elizabeth C Jones, Abhinav K Jha, Arman Rahmim, Peter J H Scott, John J Sunderland, Richard L Wahl, Sven Zuehlsdorff, Babak Saboury","doi":"10.2967/jnumed.123.266110","DOIUrl":"10.2967/jnumed.123.266110","url":null,"abstract":"<p><p>The deployment of artificial intelligence (AI) has the potential to make nuclear medicine and medical imaging faster, cheaper, and both more effective and more accessible. This is possible, however, only if clinicians and patients feel that these AI medical devices (AIMDs) are trustworthy. Highlighting the need to ensure health justice by fairly distributing benefits and burdens while respecting individual patients' rights, the AI Task Force of the Society of Nuclear Medicine and Molecular Imaging has identified 4 major ethical risks that arise during the deployment of AIMD: autonomy of patients and clinicians, transparency of clinical performance and limitations, fairness toward marginalized populations, and accountability of physicians and developers. We provide preliminary recommendations for governing these ethical risks to realize the promise of AIMD for patients and populations.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10071259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Single-Time-Point Estimates of 177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles. 177Lu PRRT吸收剂量的单时间点估计对患者管理的影响:159名患者和477个治疗周期中训练的多元线性回归模型的验证。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-10-01 Epub Date: 2023-07-27 DOI: 10.2967/jnumed.122.264923
Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J Gross, Simona Grozinsky-Glasberg, Simona Ben-Haim

Dosimetry after 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) enables estimation of radiation doses absorbed by normal organs and target lesions. This process is time-consuming and requires multiple posttreatment studies on several subsequent days. In a previous study, we described a newly developed multiple-linear-regression model to predict absorbed doses (ADs) from a single-time-point (STP) posttreatment study acquired 168 h after the first infusion and 24 h after the following ones, with similar results to the standard multiple-time-point (MTP) protocol. The present study aimed to validate this model in a large patient cohort and to assess whether STP dosimetry affects patient management decisions compared with our MTP protocol. Methods: Quantitative 177Lu-DOTATATE SPECT/CT post-PRRT data from 159 consecutive patients (172 therapies, 477 therapy cycles) were retrospectively analyzed. ADs obtained from an STP model were compared with those obtained using an MTP model. We evaluated the impact of the STP model on the decision on whether PRRT should be stopped because of an expected kidney AD exceeding the safety threshold. We hypothesized that patient management based on the STP model does not differ from that based on the MTP model in at least 90% of the cases. Results: There was no difference in management decisions between the MTP and STP models in 170 of 172 therapies (98.8%). A Fisher χ2 test for combined probabilities produced a composite P value of 0.0003. Mean cumulative AD relative differences between the STP and MTP models were 0.8% ± 8.0%, -7.7% ± 4.8%, 0.0% ± 11.4%, -2.8% ± 6.3%, and -2.1% ± 18.4% for kidneys, bone marrow, liver, spleen, and tumors, respectively (Pearson r = 0.99 for all), for patients who underwent 4 therapy cycles. Similar results were obtained with fewer therapy cycles. Conclusion: Estimated radiation ADs and patient management decisions were similar with the STP and MTP models. The STP model can simplify the dosimetry process while also reducing scanner and staff time and improving patient comfort.

177Lu DOTATATE肽受体放射性核素治疗(PRRT)后的剂量测定能够估计正常器官和靶病变吸收的辐射剂量。这个过程很耗时,需要在接下来的几天里进行多次治疗后研究。在之前的一项研究中,我们描述了一种新开发的多元线性回归模型,用于预测单时间点(STP)治疗后研究的吸收剂量(AD) 第一次输注后h和24 h,具有与标准多时间点(MTP)协议类似的结果。本研究旨在在大型患者队列中验证该模型,并评估与我们的MTP方案相比,STP剂量测定是否影响患者管理决策。方法:回顾性分析159例连续患者(172个治疗,477个治疗周期)PRRT后177Lu DOTATE SPECT/CT的定量数据。将从STP模型获得的AD与使用MTP模型获得的那些进行比较。我们评估了STP模型对是否因预期肾脏AD超过安全阈值而停止PRRT的决定的影响。我们假设,在至少90%的病例中,基于STP模型的患者管理与基于MTP模型的患者处理没有差异。结果:在172种治疗中,有170种(98.8%)的MTP和STP模型在管理决策上没有差异。Fisherχ2检验的综合概率产生0.0003的复合P值。对于接受4个治疗周期的患者,STP和MTP模型之间的平均累积AD相对差异分别为0.8%±8.0%、-7.7%±4.8%、0.0%±11.4%、-2.8%±6.3%和-2.1%±18.4%(Pearson r=0.99)。使用较少的治疗周期也获得了类似的结果。结论:估计的辐射AD和患者管理决策与STP和MTP模型相似。STP模型可以简化剂量测定过程,同时减少扫描仪和工作人员的时间,提高患者的舒适度。
{"title":"Impact of Single-Time-Point Estimates of <sup>177</sup>Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles.","authors":"Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J Gross, Simona Grozinsky-Glasberg, Simona Ben-Haim","doi":"10.2967/jnumed.122.264923","DOIUrl":"10.2967/jnumed.122.264923","url":null,"abstract":"<p><p>Dosimetry after <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) enables estimation of radiation doses absorbed by normal organs and target lesions. This process is time-consuming and requires multiple posttreatment studies on several subsequent days. In a previous study, we described a newly developed multiple-linear-regression model to predict absorbed doses (ADs) from a single-time-point (STP) posttreatment study acquired 168 h after the first infusion and 24 h after the following ones, with similar results to the standard multiple-time-point (MTP) protocol. The present study aimed to validate this model in a large patient cohort and to assess whether STP dosimetry affects patient management decisions compared with our MTP protocol. <b>Methods:</b> Quantitative <sup>177</sup>Lu-DOTATATE SPECT/CT post-PRRT data from 159 consecutive patients (172 therapies, 477 therapy cycles) were retrospectively analyzed. ADs obtained from an STP model were compared with those obtained using an MTP model. We evaluated the impact of the STP model on the decision on whether PRRT should be stopped because of an expected kidney AD exceeding the safety threshold. We hypothesized that patient management based on the STP model does not differ from that based on the MTP model in at least 90% of the cases. <b>Results:</b> There was no difference in management decisions between the MTP and STP models in 170 of 172 therapies (98.8%). A Fisher χ<sup>2</sup> test for combined probabilities produced a composite <i>P</i> value of 0.0003. Mean cumulative AD relative differences between the STP and MTP models were 0.8% ± 8.0%, -7.7% ± 4.8%, 0.0% ± 11.4%, -2.8% ± 6.3%, and -2.1% ± 18.4% for kidneys, bone marrow, liver, spleen, and tumors, respectively (Pearson <i>r</i> = 0.99 for all), for patients who underwent 4 therapy cycles. Similar results were obtained with fewer therapy cycles. <b>Conclusion:</b> Estimated radiation ADs and patient management decisions were similar with the STP and MTP models. The STP model can simplify the dosimetry process while also reducing scanner and staff time and improving patient comfort.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9883564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study. 胶质母细胞瘤前列腺特异性膜抗原的PET成像和蛋白表达:一项多中心量表研究。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.2967/jnumed.123.265738
Sanne A M van Lith, Ilanah J Pruis, Nelleke Tolboom, Tom J Snijders, Dylan Henssen, Mark Ter Laan, Maarten Te Dorsthorst, William P J Leenders, Martin Gotthardt, James Nagarajah, Pierre A Robe, Philip De Witt Hamer, Harry Hendrikse, Daniela E Oprea-Lager, Maqsood Yaqub, Ronald Boellaard, Pieter Wesseling, Rutger K Balvers, Frederik A Verburg, Anita A Harteveld, Marion Smits, Martin van den Bent, Sophie E M Veldhuijzen van Zanten, Elsmarieke van de Giessen

Upregulation of prostate-specific membrane antigen (PSMA) in neovasculature has been described in glioblastoma multiforme (GBM), whereas vasculature in nonaffected brain shows hardly any expression of PSMA. It is unclear whether PSMA-targeting tracer uptake on PET is based on PSMA-specific binding to neovasculature or aspecific uptake in tumor. Here, we quantified uptake of various PSMA-targeting tracers in GBM and correlated this with PSMA expression in tumor biopsy samples from the same patients. Methods: Fourteen patients diagnosed with de novo (n = 8) or recurrent (n = 6) GBM underwent a preoperative PET scan after injection of 1.5 MBq/kg [68Ga]Ga-PSMA-11 (n = 7), 200 MBq of [18F]DCFpyl (n = 3), or 200 MBq of [18F]PSMA-1007 (n = 4). Uptake in tumor and tumor-to-background ratios, with contralateral nonaffected brain as background, were determined. In a subset of patients, PSMA expression levels from different regions in the tumor tissue samples (n = 40), determined using immunohistochemistry (n = 35) or RNA sequencing (n = 13), were correlated with tracer uptake on PET. Results: Moderate to high (SUVmax, 1.3-20.0) heterogeneous uptake was found in all tumors irrespective of the tracer type used. Uptake in nonaffected brain was low, resulting in high tumor-to-background ratios (6.1-359.0) calculated by dividing SUVmax of tumor by SUVmax of background. Immunohistochemistry showed variable PSMA expression on endothelial cells of tumor microvasculature, as well as on dispersed individual cells (of unknown origin), and granular staining of the neuropil. No correlation was found between in vivo uptake and PSMA expression levels (for immunohistochemistry, r = -0.173, P = 0.320; for RNA, r = -0.033, P = 0.915). Conclusion: Our results indicate the potential use of various PSMA-targeting tracers in GBM. However, we found no correlation between PSMA expression levels on immunohistochemistry and uptake intensity on PET. Whether this may be explained by methodologic reasons, such as the inability to measure functionally active PSMA with immunohistochemistry, tracer pharmacokinetics, or the contribution of a disturbed blood-brain barrier to tracer retention, should still be investigated.

在多形性胶质母细胞瘤(GBM)中,新血管系统中前列腺特异性膜抗原(PSMA)的上调已被描述,而在未受影响的大脑中,血管系统几乎没有PSMA的表达。目前尚不清楚PSMA靶向PET示踪剂摄取是基于PSMA与新血管系统的特异性结合还是基于肿瘤中的特异性摄取。在这里,我们量化了GBM中各种PSMA靶向示踪剂的摄取,并将其与来自相同患者的肿瘤活检样本中PSMA的表达相关联。方法:14名被诊断为新发(n=8)或复发(n=6)GBM的患者在注射1.5MBq/kg[68Ga]Ga-PSMA-11(n=7)、200MBq[18F]DCFpyl(n=3)或200MBq[108F]PSMA-1007(n=4)后,进行了术前PET扫描。以对侧未受影响的大脑为背景,测定肿瘤摄取量和肿瘤与背景的比率。在一组患者中,使用免疫组织化学(n=35)或RNA测序(n=13)测定的肿瘤组织样本(n=40)中不同区域的PSMA表达水平与PET上的示踪剂摄取相关。结果:无论使用何种示踪剂,在所有肿瘤中都发现了中等至高(SUVmax,1.3-20.0)的异质性摄取。未受影响的大脑摄取量较低,导致肿瘤与背景的比值较高(6.1-359.0),通过将肿瘤的SUVmax除以背景的SUVmax。免疫组织化学显示,PSMA在肿瘤微血管内皮细胞以及分散的单个细胞(来源不明)上的表达可变,神经胶质颗粒染色。体内摄取与PSMA表达水平之间没有相关性(免疫组化,r=-0.173,P=0.320;RNA,r=-0.033,P=0.915)。结论:我们的结果表明各种PSMA靶向示踪剂在GBM中的潜在用途。然而,我们发现PSMA在免疫组织化学上的表达水平与PET上的摄取强度之间没有相关性。这是否可以通过方法学原因来解释,例如无法用免疫组织化学、示踪剂药代动力学测量功能活性PSMA,或者血脑屏障紊乱对示踪剂保留的贡献,仍需研究。
{"title":"PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.","authors":"Sanne A M van Lith,&nbsp;Ilanah J Pruis,&nbsp;Nelleke Tolboom,&nbsp;Tom J Snijders,&nbsp;Dylan Henssen,&nbsp;Mark Ter Laan,&nbsp;Maarten Te Dorsthorst,&nbsp;William P J Leenders,&nbsp;Martin Gotthardt,&nbsp;James Nagarajah,&nbsp;Pierre A Robe,&nbsp;Philip De Witt Hamer,&nbsp;Harry Hendrikse,&nbsp;Daniela E Oprea-Lager,&nbsp;Maqsood Yaqub,&nbsp;Ronald Boellaard,&nbsp;Pieter Wesseling,&nbsp;Rutger K Balvers,&nbsp;Frederik A Verburg,&nbsp;Anita A Harteveld,&nbsp;Marion Smits,&nbsp;Martin van den Bent,&nbsp;Sophie E M Veldhuijzen van Zanten,&nbsp;Elsmarieke van de Giessen","doi":"10.2967/jnumed.123.265738","DOIUrl":"10.2967/jnumed.123.265738","url":null,"abstract":"<p><p>Upregulation of prostate-specific membrane antigen (PSMA) in neovasculature has been described in glioblastoma multiforme (GBM), whereas vasculature in nonaffected brain shows hardly any expression of PSMA. It is unclear whether PSMA-targeting tracer uptake on PET is based on PSMA-specific binding to neovasculature or aspecific uptake in tumor. Here, we quantified uptake of various PSMA-targeting tracers in GBM and correlated this with PSMA expression in tumor biopsy samples from the same patients. <b>Methods:</b> Fourteen patients diagnosed with de novo (<i>n</i> = 8) or recurrent (<i>n</i> = 6) GBM underwent a preoperative PET scan after injection of 1.5 MBq/kg [<sup>68</sup>Ga]Ga-PSMA-11 (<i>n</i> = 7), 200 MBq of [<sup>18</sup>F]DCFpyl (<i>n</i> = 3), or 200 MBq of [<sup>18</sup>F]PSMA-1007 (<i>n</i> = 4). Uptake in tumor and tumor-to-background ratios, with contralateral nonaffected brain as background, were determined. In a subset of patients, PSMA expression levels from different regions in the tumor tissue samples (<i>n</i> = 40), determined using immunohistochemistry (<i>n</i> = 35) or RNA sequencing (<i>n</i> = 13), were correlated with tracer uptake on PET. <b>Results:</b> Moderate to high (SUV<sub>max</sub>, 1.3-20.0) heterogeneous uptake was found in all tumors irrespective of the tracer type used. Uptake in nonaffected brain was low, resulting in high tumor-to-background ratios (6.1-359.0) calculated by dividing SUV<sub>max</sub> of tumor by SUV<sub>max</sub> of background. Immunohistochemistry showed variable PSMA expression on endothelial cells of tumor microvasculature, as well as on dispersed individual cells (of unknown origin), and granular staining of the neuropil. No correlation was found between in vivo uptake and PSMA expression levels (for immunohistochemistry, <i>r</i> = -0.173, <i>P</i> = 0.320; for RNA, <i>r</i> = -0.033, <i>P</i> = 0.915). <b>Conclusion:</b> Our results indicate the potential use of various PSMA-targeting tracers in GBM. However, we found no correlation between PSMA expression levels on immunohistochemistry and uptake intensity on PET. Whether this may be explained by methodologic reasons, such as the inability to measure functionally active PSMA with immunohistochemistry, tracer pharmacokinetics, or the contribution of a disturbed blood-brain barrier to tracer retention, should still be investigated.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10483759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stacking Ensemble Learning-Based [18F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma. 基于堆叠集成学习[18F]FDG PET放射组学用于弥漫性大B细胞淋巴瘤的预后预测。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-07-27 DOI: 10.2967/jnumed.122.265244
Shuilin Zhao, Jing Wang, Chentao Jin, Xiang Zhang, Chenxi Xue, Rui Zhou, Yan Zhong, Yuwei Liu, Xuexin He, Youyou Zhou, Caiyun Xu, Lixia Zhang, Wenbin Qian, Hong Zhang, Xiaohui Zhang, Mei Tian

This study aimed to develop an analytic approach based on [18F]FDG PET radiomics using stacking ensemble learning to improve the outcome prediction in diffuse large B-cell lymphoma (DLBCL). Methods: In total, 240 DLBCL patients from 2 medical centers were divided into the training set (n = 141), internal testing set (n = 61), and external testing set (n = 38). Radiomics features were extracted from pretreatment [18F]FDG PET scans at the patient level using 4 semiautomatic segmentation methods (SUV threshold of 2.5, SUV threshold of 4.0 [SUV4.0], 41% of SUVmax, and SUV threshold of mean liver uptake [PERCIST]). All extracted features were harmonized with the ComBat method. The intraclass correlation coefficient was used to evaluate the reliability of radiomics features extracted by different segmentation methods. Features from the most reliable segmentation method were selected by Pearson correlation coefficient analysis and the LASSO (least absolute shrinkage and selection operator) algorithm. A stacking ensemble learning approach was applied to build radiomics-only and combined clinical-radiomics models for prediction of 2-y progression-free survival and overall survival based on 4 machine learning classifiers (support vector machine, random forests, gradient boosting decision tree, and adaptive boosting). Confusion matrix, receiver-operating-characteristic curve analysis, and survival analysis were used to evaluate the model performance. Results: Among 4 semiautomatic segmentation methods, SUV4.0 segmentation yielded the highest interobserver reliability, with 830 (66.7%) selected radiomics features. The combined model constructed by the stacking method achieved the best discrimination performance. For progression-free survival prediction in the external testing set, the areas under the receiver-operating-characteristic curve and accuracy of the stacking-based combined model were 0.771 and 0.789, respectively. For overall survival prediction, the stacking-based combined model achieved an area under the curve of 0.725 and an accuracy of 0.763 in the external testing set. The combined model also demonstrated a more distinct risk stratification than the International Prognostic Index in all sets (log-rank test, all P < 0.05). Conclusion: The combined model that incorporates [18F]FDG PET radiomics and clinical characteristics based on stacking ensemble learning could enable improved risk stratification in DLBCL.

本研究旨在开发一种基于[18F]FDG PET放射组学的分析方法,使用堆叠集成学习来改进弥漫性大B细胞淋巴瘤(DLBCL)的预后预测。方法:将来自2个医疗中心的240名DLBCL患者分为训练集(n=141)、内部测试集(n=61)和外部测试集(n=38)。使用4种半自动分割方法(SUV阈值为2.5,SUV阈值为4.0[SUV4.0],SUVmax的41%,平均肝脏摄取的SUV阈值[PERIST])从患者水平的预处理[18F]FDG PET扫描中提取放射组学特征。所有提取的特征都与ComBat方法进行了协调。组内相关系数用于评估通过不同分割方法提取的放射组学特征的可靠性。通过Pearson相关系数分析和LASSO(最小绝对收缩和选择算子)算法从最可靠的分割方法中选择特征。基于4个机器学习分类器(支持向量机、随机森林、梯度增强决策树和自适应增强),应用堆叠集成学习方法构建仅用于放射组学和组合临床放射组学的模型,用于预测2-y无进展生存期和总生存期。使用混淆矩阵、受试者操作特征曲线分析和生存分析来评估模型性能。结果:在4种半自动分割方法中,SUV4.0分割产生了最高的观察者间可靠性,有830个(66.7%)选择了放射组学特征。采用叠加方法构建的组合模型具有最佳的识别性能。对于外部测试集中的无进展生存期预测,基于叠加的组合模型的受试者工作特性曲线下的面积和准确性分别为0.771和0.789。对于整体生存预测,基于堆叠的组合模型在外部测试集中实现了0.725的曲线下面积和0.763的精度。在所有集合中,联合模型也显示出比国际预后指数更明显的风险分层(log-rank检验,均P<0.05)。结论:结合[18F]FDG PET放射组学和基于堆叠集合学习的临床特征的联合模型可以改善DLBCL的风险分层。
{"title":"Stacking Ensemble Learning-Based [<sup>18</sup>F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma.","authors":"Shuilin Zhao,&nbsp;Jing Wang,&nbsp;Chentao Jin,&nbsp;Xiang Zhang,&nbsp;Chenxi Xue,&nbsp;Rui Zhou,&nbsp;Yan Zhong,&nbsp;Yuwei Liu,&nbsp;Xuexin He,&nbsp;Youyou Zhou,&nbsp;Caiyun Xu,&nbsp;Lixia Zhang,&nbsp;Wenbin Qian,&nbsp;Hong Zhang,&nbsp;Xiaohui Zhang,&nbsp;Mei Tian","doi":"10.2967/jnumed.122.265244","DOIUrl":"10.2967/jnumed.122.265244","url":null,"abstract":"<p><p>This study aimed to develop an analytic approach based on [<sup>18</sup>F]FDG PET radiomics using stacking ensemble learning to improve the outcome prediction in diffuse large B-cell lymphoma (DLBCL). <b>Methods:</b> In total, 240 DLBCL patients from 2 medical centers were divided into the training set (<i>n</i> = 141), internal testing set (<i>n</i> = 61), and external testing set (<i>n</i> = 38). Radiomics features were extracted from pretreatment [<sup>18</sup>F]FDG PET scans at the patient level using 4 semiautomatic segmentation methods (SUV threshold of 2.5, SUV threshold of 4.0 [SUV4.0], 41% of SUV<sub>max</sub>, and SUV threshold of mean liver uptake [PERCIST]). All extracted features were harmonized with the ComBat method. The intraclass correlation coefficient was used to evaluate the reliability of radiomics features extracted by different segmentation methods. Features from the most reliable segmentation method were selected by Pearson correlation coefficient analysis and the LASSO (least absolute shrinkage and selection operator) algorithm. A stacking ensemble learning approach was applied to build radiomics-only and combined clinical-radiomics models for prediction of 2-y progression-free survival and overall survival based on 4 machine learning classifiers (support vector machine, random forests, gradient boosting decision tree, and adaptive boosting). Confusion matrix, receiver-operating-characteristic curve analysis, and survival analysis were used to evaluate the model performance. <b>Results:</b> Among 4 semiautomatic segmentation methods, SUV4.0 segmentation yielded the highest interobserver reliability, with 830 (66.7%) selected radiomics features. The combined model constructed by the stacking method achieved the best discrimination performance. For progression-free survival prediction in the external testing set, the areas under the receiver-operating-characteristic curve and accuracy of the stacking-based combined model were 0.771 and 0.789, respectively. For overall survival prediction, the stacking-based combined model achieved an area under the curve of 0.725 and an accuracy of 0.763 in the external testing set. The combined model also demonstrated a more distinct risk stratification than the International Prognostic Index in all sets (log-rank test, all <i>P</i> < 0.05). <b>Conclusion:</b> The combined model that incorporates [<sup>18</sup>F]FDG PET radiomics and clinical characteristics based on stacking ensemble learning could enable improved risk stratification in DLBCL.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9883566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Not All Gatekeepers Are Theranostics. 并非所有的看门人都是Theranos。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-06-29 DOI: 10.2967/jnumed.123.266006
Dale L Bailey
TO THE EDITOR: Sometimes we need to challenge the views of colleagues and friends, especially when their thinking has the effect of muddying the waters rather than providing greater insight and clarity. I believe this to be the case with the opinion piece by Weber et al. in the May 2023 issue of the journal (1). The authors seek to redefine the term theranostic. They assert that this is any molecular imaging probe that provides actionable information for any subsequent therapeutic. This includes medical therapies, radiation therapy, surgery, or cell therapies. I believe that, in doing so, they are losing the very essence of what a theranostic is. I agree with the authors that the therapeutic component of a theranostic pair need not be a radionuclide therapy, but I contend that it mustbe the same(oravery similar)moleculeormoiety. It couldbecarrying a toxic therapeutic or it may be an antibody that targets a protein (e.g., amyloid in the brain), but it has to be the same targeting moiety. What the authors of this article are referring to as a theranostic imaging probe when used with a range of other therapies is more accurately described by the term gatekeeper or companion diagnostic. The imaging study validates the use of a certain therapeutic approach: this is not theranostics but simply a good use of medical imaging. The authors surely would not contend that a ventilation–perfusion lung scan demonstrating a pulmonary embolism that was subsequently treated with anticoagulation was a theranostic approach. Definitions are important and help us to describe and conceptualize the strategy chosen to diagnose and treat diseases. Seeking to dilute the definition of a theranostic in the way the authors have done will have the effect of confusing the basis of the concept and will be unhelpful. The theranostic approach is an extremely powerful one and should be amajor focus of future developments inmolecular imaging and therapy. We need to keep the concepts clear and appreciate the differences between gatekeeper and theranostic approaches. They are both very important, but they are not the same. Not all gatekeepers are theranostics.
{"title":"Not All Gatekeepers Are Theranostics.","authors":"Dale L Bailey","doi":"10.2967/jnumed.123.266006","DOIUrl":"10.2967/jnumed.123.266006","url":null,"abstract":"TO THE EDITOR: Sometimes we need to challenge the views of colleagues and friends, especially when their thinking has the effect of muddying the waters rather than providing greater insight and clarity. I believe this to be the case with the opinion piece by Weber et al. in the May 2023 issue of the journal (1). The authors seek to redefine the term theranostic. They assert that this is any molecular imaging probe that provides actionable information for any subsequent therapeutic. This includes medical therapies, radiation therapy, surgery, or cell therapies. I believe that, in doing so, they are losing the very essence of what a theranostic is. I agree with the authors that the therapeutic component of a theranostic pair need not be a radionuclide therapy, but I contend that it mustbe the same(oravery similar)moleculeormoiety. It couldbecarrying a toxic therapeutic or it may be an antibody that targets a protein (e.g., amyloid in the brain), but it has to be the same targeting moiety. What the authors of this article are referring to as a theranostic imaging probe when used with a range of other therapies is more accurately described by the term gatekeeper or companion diagnostic. The imaging study validates the use of a certain therapeutic approach: this is not theranostics but simply a good use of medical imaging. The authors surely would not contend that a ventilation–perfusion lung scan demonstrating a pulmonary embolism that was subsequently treated with anticoagulation was a theranostic approach. Definitions are important and help us to describe and conceptualize the strategy chosen to diagnose and treat diseases. Seeking to dilute the definition of a theranostic in the way the authors have done will have the effect of confusing the basis of the concept and will be unhelpful. The theranostic approach is an extremely powerful one and should be amajor focus of future developments inmolecular imaging and therapy. We need to keep the concepts clear and appreciate the differences between gatekeeper and theranostic approaches. They are both very important, but they are not the same. Not all gatekeepers are theranostics.","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9698301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Potential of 188Re as an Alternative to 177Lu and Dosimetric Consequences. 188Re作为177Lu替代品的潜力及其剂量学后果。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-03 DOI: 10.2967/jnumed.123.265782
Marc Pretze, Jörg Kotzerke, Robert Freudenberg, Claudia Brogsitter
{"title":"Potential of <sup>188</sup>Re as an Alternative to <sup>177</sup>Lu and Dosimetric Consequences.","authors":"Marc Pretze, Jörg Kotzerke, Robert Freudenberg, Claudia Brogsitter","doi":"10.2967/jnumed.123.265782","DOIUrl":"10.2967/jnumed.123.265782","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study. 68Ga-SSO-120 PET用于小细胞肺癌癌症患者的初步分期:一项单中心回顾性研究。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-07-20 DOI: 10.2967/jnumed.123.265664
David Kersting, Patrick Sandach, Miriam Sraieb, Marcel Wiesweg, Martin Metzenmacher, Kaid Darwiche, Filiz Oezkan, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Rainer Hamacher, Wolfgang P Fendler, Johannes Wienker, Wilfried E E Eberhardt, Martin Schuler, Ken Herrmann, Hubertus Hautzel

PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan (SSO-120, previously OPS-202) could offer accurate tumor detection and screening for SSTR2-antagonist radionuclide therapy in patients with SSTR2-expressing small cell lung cancer (SCLC). The aim of this single-center study was to investigate tumor uptake and detection rates of 68Ga-SSO-120 in comparison to 18F-FDG PET in the initial staging of SCLC patients. Methods: Patients with newly diagnosed SCLC who underwent additional whole-body 68Ga-SSO-120 PET/CT during the initial diagnostic workup were retrospectively included. The mean administered activity was 139 MBq, and the mean uptake time was 60 min. Gold-standard staging 18F-FDG PET/CT was evaluated if available within 2 wk before or after 68Ga-SSO-120 PET if morphologic differences in CT images were absent. 68Ga-SSO-120- or 18F-FDG-positive lesions were reported in 7 anatomic regions (primary tumor, thoracic lymph node metastases, and distant metastases including pleural, contralateral pulmonary, liver, bone, and other) according to the TNM classification for lung cancer (eighth edition). Consensus TNM staging (derived from CT, endobronchial ultrasound-guided transbronchial needle aspiration, PET, and brain MRI) by a clinical tumor board served as the reference standard. Results: Thirty-one patients were included, 12 with limited and 19 with extensive disease according to the Veterans Administration Lung Study Group classification. 68Ga-SSO-120-positive tumor was detected in all patients (100%) and in 90 of the 217 evaluated regions (41.5%). Thirteen patients (42.0%) had intense average 68Ga-SSO-120 uptake (region-based mean SUVmax ≥ 10); 28 patients (90.3%) had average 68Ga-SSO-120 uptake greater than liver uptake (region-based mean peak tumor-to-liver ratio > 1). In 25 patients with evaluable 18F-FDG PET, primary tumor, thoracic lymph node metastases, and distant metastases were detected in 100%, 92%, and 64%, respectively, of all investigated patients by 68Ga-SSO-120 and in 100%, 92%, and 56%, respectively, by 18F-FDG PET. 68Ga-SSO-120 PET detected additional contralateral lymph node, liver, and brain metastases in 1, 1, and 2 patients, respectively (no histopathology available), and 18F-FDG PET detected additional contralateral lymph node metastases in 3 patients (1 confirmed, 1 systematic endobronchial ultrasound-guided transbronchial needle aspiration-negative, and 1 without available histopathology). None of these differences altered Veterans Administration Lung Study Group staging. The region-based monotonic correlation between 68Ga-SSO-120 and 18F-FDG uptake was low (Spearman ρ = 0.26-0.33). Conclusion: 68Ga-SSO-120 PET offers high diagnostic precision with compara

使用生长抑素受体2(SSTR2)拮抗剂沙多核苷酸三唑菌坦(SSO-120,以前为OPS-202)的PET成像可以为癌症小细胞肺癌(SCLC)患者提供SSTR2放射性核素治疗的准确肿瘤检测和筛查。这项单中心研究的目的是研究68Ga-SSO-120与18F-FDG PET在SCLC患者初始分期中的肿瘤摄取和检测率。方法:回顾性纳入在初次诊断检查中接受额外全身68Ga-SSO-120 PET/CT的新诊断SCLC患者。平均给药活性为139MBq,平均摄取时间为60 min。如果在68Ga-SSO-120 PET之前或之后2周内可用,如果CT图像中没有形态学差异,则评估18F-FDG PET/CT的金标准分期。根据癌症TNM分类(第八版),在7个解剖区域(原发肿瘤、胸淋巴结转移和远处转移,包括胸膜、对侧肺、肝、骨和其他)报告了68Ga-SSO-120-或18F-FDG阳性病变。临床肿瘤委员会的一致TNM分期(来源于CT、支气管内超声引导下经支气管针吸、PET和脑MRI)作为参考标准。结果:根据退伍军人管理局肺部研究组的分类,31名患者被纳入,12名为局限性疾病,19名为广泛性疾病。在所有患者(100%)和217个评估区域中的90个区域(41.5%)中检测到68Ga-SSO-120阳性肿瘤。13名患者(42.0%)具有强烈的68Ga-SSO-120平均摄取(基于区域的平均SUVmax≥10);28名患者(90.3%)的68Ga-SSO-120平均摄取量大于肝脏摄取量(基于区域的肿瘤与肝脏的平均峰值比值>1)。在25例可评估的18F-FDG PET患者中,68Ga-SSO-120检测到的原发性肿瘤、胸淋巴结转移和远处转移分别占所有研究患者的100%、92%和64%,18F-FDG-PET检测到的分别为100%、92%、56%。68Ga-SSO-120 PET分别在1例、1例和2例患者中检测到额外的对侧淋巴结、肝脏和大脑转移(无组织病理学可用),18F-FDG PET在3例患者中发现额外的对一侧淋巴结转移(1例确诊,1例系统性支气管内超声引导下经支气管针抽吸阴性,1例无组织病理学家可用)。这些差异均未改变退伍军人管理局肺部研究组的分期。68Ga-SSO-120和18F-FDG摄取之间基于区域的单调相关性较低(Spearmanρ = 0.26-0.33)。结论:68Ga-SSO-120 PET具有较高的诊断精度,具有与金标准18F-FDG PET相当的检测率和额外的补充信息。大多数患者的持续摄取保证了对SSTR2定向放射性核素治疗的探索。
{"title":"<sup>68</sup>Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.","authors":"David Kersting,&nbsp;Patrick Sandach,&nbsp;Miriam Sraieb,&nbsp;Marcel Wiesweg,&nbsp;Martin Metzenmacher,&nbsp;Kaid Darwiche,&nbsp;Filiz Oezkan,&nbsp;Servet Bölükbas,&nbsp;Martin Stuschke,&nbsp;Lale Umutlu,&nbsp;Michael Nader,&nbsp;Rainer Hamacher,&nbsp;Wolfgang P Fendler,&nbsp;Johannes Wienker,&nbsp;Wilfried E E Eberhardt,&nbsp;Martin Schuler,&nbsp;Ken Herrmann,&nbsp;Hubertus Hautzel","doi":"10.2967/jnumed.123.265664","DOIUrl":"10.2967/jnumed.123.265664","url":null,"abstract":"<p><p>PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan (SSO-120, previously OPS-202) could offer accurate tumor detection and screening for SSTR2-antagonist radionuclide therapy in patients with SSTR2-expressing small cell lung cancer (SCLC). The aim of this single-center study was to investigate tumor uptake and detection rates of <sup>68</sup>Ga-SSO-120 in comparison to <sup>18</sup>F-FDG PET in the initial staging of SCLC patients. <b>Methods:</b> Patients with newly diagnosed SCLC who underwent additional whole-body <sup>68</sup>Ga-SSO-120 PET/CT during the initial diagnostic workup were retrospectively included. The mean administered activity was 139 MBq, and the mean uptake time was 60 min. Gold-standard staging <sup>18</sup>F-FDG PET/CT was evaluated if available within 2 wk before or after <sup>68</sup>Ga-SSO-120 PET if morphologic differences in CT images were absent. <sup>68</sup>Ga-SSO-120- or <sup>18</sup>F-FDG-positive lesions were reported in 7 anatomic regions (primary tumor, thoracic lymph node metastases, and distant metastases including pleural, contralateral pulmonary, liver, bone, and other) according to the TNM classification for lung cancer (eighth edition). Consensus TNM staging (derived from CT, endobronchial ultrasound-guided transbronchial needle aspiration, PET, and brain MRI) by a clinical tumor board served as the reference standard. <b>Results:</b> Thirty-one patients were included, 12 with limited and 19 with extensive disease according to the Veterans Administration Lung Study Group classification. <sup>68</sup>Ga-SSO-120-positive tumor was detected in all patients (100%) and in 90 of the 217 evaluated regions (41.5%). Thirteen patients (42.0%) had intense average <sup>68</sup>Ga-SSO-120 uptake (region-based mean SUV<sub>max</sub> ≥ 10); 28 patients (90.3%) had average <sup>68</sup>Ga-SSO-120 uptake greater than liver uptake (region-based mean peak tumor-to-liver ratio > 1). In 25 patients with evaluable <sup>18</sup>F-FDG PET, primary tumor, thoracic lymph node metastases, and distant metastases were detected in 100%, 92%, and 64%, respectively, of all investigated patients by <sup>68</sup>Ga-SSO-120 and in 100%, 92%, and 56%, respectively, by <sup>18</sup>F-FDG PET. <sup>68</sup>Ga-SSO-120 PET detected additional contralateral lymph node, liver, and brain metastases in 1, 1, and 2 patients, respectively (no histopathology available), and <sup>18</sup>F-FDG PET detected additional contralateral lymph node metastases in 3 patients (1 confirmed, 1 systematic endobronchial ultrasound-guided transbronchial needle aspiration-negative, and 1 without available histopathology). None of these differences altered Veterans Administration Lung Study Group staging. The region-based monotonic correlation between <sup>68</sup>Ga-SSO-120 and <sup>18</sup>F-FDG uptake was low (Spearman ρ = 0.26-0.33). <b>Conclusion:</b> <sup>68</sup>Ga-SSO-120 PET offers high diagnostic precision with compara","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer. 68Ga-PSMA PET/CT用于223Ra治疗转移性前列腺癌的疗效评估。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-03 DOI: 10.2967/jnumed.123.265489
Anouk C de Jong, Marcel Segbers, Sui Wai Ling, Laura H Graven, Niven Mehra, Paul Hamberg, Tessa Brabander, Ronald de Wit, Astrid A M van der Veldt

CT and bone scintigraphy are not useful for response evaluation of bone metastases to 223Ra treatment in metastatic castration-resistant prostate cancer (mCRPC). PET using 68Ga prostate-specific membrane antigen 11 (68Ga-PSMA) is a promising tool for response evaluation of mCRPC. The aim of this study was to determine the utility of 68Ga-PSMA PET/CT for response evaluation of 223Ra treatment in patients with mCRPC. Methods: Within this prospective, multicenter, imaging discovery study, 28 patients with mCRPC, eligible for 223Ra treatment, were included between 2019 and 2022. Patients received 223Ra according to the standard of care. Study procedures included CT, bone scintigraphy, and 68Ga-PSMA PET/CT at baseline, after 3 and 6 cycles of 223Ra treatment, and on treatment failure. Response to 223Ra treatment was visually assessed on all 3 imaging modalities. Total tumor volume within bone (TTVbone) was determined on 68Ga-PSMA PET/CT. Intrapatient heterogeneity in response was studied using a newly developed image-registration tool for sequential images of PET/CT. Results were compared with failure-free survival (good responders vs. poor responders; cutoff, 24 wk) and alkaline phosphatase (ALP) response after 3 cycles. Results: Visual response assessment criteria could not distinguish good responders from poor responders on 68Ga-PSMA PET/CT and bone scintigraphy. For 68Ga-PSMA PET/CT, TTVbone at baseline was lower in good responders than in poor responders, whereas TTVbone increased in both groups during treatment. TTVbone was higher in patients with new extraosseous metastases during 223Ra treatment. Although TTVbone and ALP correlated at baseline, changes in TTVbone and ALP on treatment did not. 68Ga-PSMA response of TTVbone showed intrapatient heterogeneity in most patients. Conclusion: mCRPC patients with lower TTVbone on 68Ga-PSMA PET/CT have the best clinical outcome after 223Ra treatment. Response is highly heterogeneous in most patients. A decrease in ALP, which occurred in most patients, was not correlated with a decrease in TTVbone, which might make one question the value of ALP for disease monitoring during 223Ra treatment in clinical practice.

CT和骨闪烁扫描对转移性去势耐受性癌症(mCRPC)223Ra治疗的骨转移反应评估没有用处。使用68Ga前列腺特异性膜抗原11(68Ga-PSMA)的PET是用于mCRPC反应评估的有前途的工具。本研究的目的是确定68Ga-PSMA PET/CT在mCRPC患者223Ra治疗反应评估中的效用。方法:在这项前瞻性、多中心、影像学发现研究中,纳入了2019年至2022年间符合223Ra治疗条件的28名mCRPC患者。根据护理标准,患者接受223Ra治疗。研究程序包括基线时、223Ra治疗3个和6个周期后以及治疗失败时的CT、骨闪烁扫描和68Ga-PSMA PET/CT。在所有3种成像模式上对223Ra治疗的反应进行视觉评估。在68Ga-PSMA PET/CT上测定骨内肿瘤总体积(TTVbone)。使用新开发的PET/CT序列图像图像配准工具研究了患者反应的异质性。将结果与3个周期后的无故障生存率(良好反应者与不良反应者;截止时间,24周)和碱性磷酸酶(ALP)反应进行比较。结果:在68Ga-PSMA PET/CT和骨闪烁扫描上,视觉反应评估标准无法区分良好反应者和不良反应者。对于68Ga PSMA PET/CT,良好应答者基线时的TTVbone低于不良应答者,而两组在治疗期间的TTVbone均增加。在223Ra治疗期间,新的骨外转移患者的TTVbone较高。尽管TTVbone和ALP在基线时相关,但治疗后TTVbon和ALP的变化并不相关。TTVbone的68Ga-PSMA反应在大多数患者中显示出患者内的异质性。结论:应用68Ga PSMA PET/CT显像对TTVbone较低的mCRPC患者进行223Ra治疗后,临床效果最佳。大多数患者的反应具有高度异质性。ALP的下降发生在大多数患者中,与TTVbone的下降无关,这可能会使人们对临床实践中223Ra治疗期间ALP对疾病监测的价值产生疑问。
{"title":"<sup>68</sup>Ga-PSMA PET/CT for Response Evaluation of <sup>223</sup>Ra Treatment in Metastatic Prostate Cancer.","authors":"Anouk C de Jong,&nbsp;Marcel Segbers,&nbsp;Sui Wai Ling,&nbsp;Laura H Graven,&nbsp;Niven Mehra,&nbsp;Paul Hamberg,&nbsp;Tessa Brabander,&nbsp;Ronald de Wit,&nbsp;Astrid A M van der Veldt","doi":"10.2967/jnumed.123.265489","DOIUrl":"10.2967/jnumed.123.265489","url":null,"abstract":"<p><p>CT and bone scintigraphy are not useful for response evaluation of bone metastases to <sup>223</sup>Ra treatment in metastatic castration-resistant prostate cancer (mCRPC). PET using <sup>68</sup>Ga prostate-specific membrane antigen 11 (<sup>68</sup>Ga-PSMA) is a promising tool for response evaluation of mCRPC. The aim of this study was to determine the utility of <sup>68</sup>Ga-PSMA PET/CT for response evaluation of <sup>223</sup>Ra treatment in patients with mCRPC. <b>Methods:</b> Within this prospective, multicenter, imaging discovery study, 28 patients with mCRPC, eligible for <sup>223</sup>Ra treatment, were included between 2019 and 2022. Patients received <sup>223</sup>Ra according to the standard of care. Study procedures included CT, bone scintigraphy, and <sup>68</sup>Ga-PSMA PET/CT at baseline, after 3 and 6 cycles of <sup>223</sup>Ra treatment, and on treatment failure. Response to <sup>223</sup>Ra treatment was visually assessed on all 3 imaging modalities. Total tumor volume within bone (TTV<sub>bone</sub>) was determined on <sup>68</sup>Ga-PSMA PET/CT. Intrapatient heterogeneity in response was studied using a newly developed image-registration tool for sequential images of PET/CT. Results were compared with failure-free survival (good responders vs. poor responders; cutoff, 24 wk) and alkaline phosphatase (ALP) response after 3 cycles. <b>Results:</b> Visual response assessment criteria could not distinguish good responders from poor responders on <sup>68</sup>Ga-PSMA PET/CT and bone scintigraphy. For <sup>68</sup>Ga-PSMA PET/CT, TTV<sub>bone</sub> at baseline was lower in good responders than in poor responders, whereas TTV<sub>bone</sub> increased in both groups during treatment. TTV<sub>bone</sub> was higher in patients with new extraosseous metastases during <sup>223</sup>Ra treatment. Although TTV<sub>bone</sub> and ALP correlated at baseline, changes in TTV<sub>bone</sub> and ALP on treatment did not. <sup>68</sup>Ga-PSMA response of TTV<sub>bone</sub> showed intrapatient heterogeneity in most patients. <b>Conclusion:</b> mCRPC patients with lower TTV<sub>bone</sub> on <sup>68</sup>Ga-PSMA PET/CT have the best clinical outcome after <sup>223</sup>Ra treatment. Response is highly heterogeneous in most patients. A decrease in ALP, which occurred in most patients, was not correlated with a decrease in TTV<sub>bone</sub>, which might make one question the value of ALP for disease monitoring during <sup>223</sup>Ra treatment in clinical practice.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9936954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis. [68Ga]Ga-FAPI-46 PET用于梗死后肾纤维化的可视化。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-10-01 Epub Date: 2023-06-15 DOI: 10.2967/jnumed.123.265640
Lena M Unterrainer, Anthony E Sisk, Johannes Czernin, Brian M Shuch, Jeremie Calais, Masatoshi Hotta
.
{"title":"[<sup>68</sup>Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis.","authors":"Lena M Unterrainer,&nbsp;Anthony E Sisk,&nbsp;Johannes Czernin,&nbsp;Brian M Shuch,&nbsp;Jeremie Calais,&nbsp;Masatoshi Hotta","doi":"10.2967/jnumed.123.265640","DOIUrl":"10.2967/jnumed.123.265640","url":null,"abstract":".","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9995544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of Nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1